ABSTRACT
BACKGROUND: Schizophrenia patients present deficits in social cognition (SC), emotion and social perception, theory of mind (ToM), and attributional style. This study tested the efficacy, in real clinical conditions, of a online self-training program in SC, e-Motional Training®, in comparison with treatment as usual. METHOD: A randomized single-blinded multicenter clinical trial was conducted with 60 schizophrenia stable outpatients. All patients (control and intervention) were treated with drug therapy, case management, and individual and group psychotherapy (not focused on SC). Intervention group was treated with e-Motional Training®, an online program devised for SC rehabilitation. STATISTICAL ANALYSIS: A descriptive analysis and parametric/non-parametric tests were used to compare both groups at baseline. Analysis of covariance was used to compared post-pre changes in SC between the two interventions. If the group effect was significant, follow-up univariate test (t-test for dependent samples) was carried out in each group to verify whether the effect was due to improvement in the intervention group or deterioration in the control group. We considered statistically significant differences with P < 0.05. RESULTS: Significant improvements were obtained in the intervention group in emotion recognition and most ToM variables in comparison with the control group. DISCUSSION: e-Motional Training® seems to be a promising online training tool for SC deficits in schizophrenia, covering the lack of similar intervention instruments in our community.
Subject(s)
Antidepressive Agents/adverse effects , Delirium/chemically induced , Depressive Disorder, Major/drug therapy , Venlafaxine Hydrochloride/adverse effects , Aged , Antidepressive Agents/administration & dosage , Antidepressive Agents/pharmacokinetics , Comorbidity , Confusion/chemically induced , Delirium/drug therapy , Depressive Disorder, Major/psychology , Dopamine/metabolism , Dose-Response Relationship, Drug , Drug Substitution , Drug Synergism , Female , Humans , Lorazepam/therapeutic use , Models, Neurological , Norepinephrine/physiology , Polypharmacy , Psychotropic Drugs/administration & dosage , Psychotropic Drugs/therapeutic use , Recurrence , Sertraline/pharmacokinetics , Sertraline/therapeutic use , Venlafaxine Hydrochloride/administration & dosage , Venlafaxine Hydrochloride/pharmacokineticsABSTRACT
No disponible
Subject(s)
Female , Humans , Delirium/metabolism , Delirium/psychology , Central Nervous System Diseases/chemically induced , Central Nervous System Diseases/metabolism , Oxidative Stress/genetics , Uterine Cervical Diseases/drug therapy , Uterine Cervical Diseases/radiotherapy , Delirium/complications , Delirium/diagnosis , Central Nervous System Diseases/complications , Central Nervous System Diseases/diagnosis , Oxidative Stress/physiology , Uterine Cervical Diseases/rehabilitation , Uterine Cervical Diseases/therapyABSTRACT
INTRODUCTION: Antiphospholipid syndrome (APS) is an autoimmune disorder which causes an hypercoagulation state characterized by thrombotic events, repetitive miscarriages and the presence of antiphospholipid antibodies. APS may be an isolated disease (primary APS) or associated to systemic lupus erythematous or another autoimmune conditions (secondary APS). Neuropsychiatric manifestations accompanying APS include migraine, epilepsy, chorea, dementia or psychosis. Detailed descriptions of clinical cases are lacking, and correlations between clinical and analytical findings are far from being well known. We review literature concerning neuropsychiatric manifestations in general and psychosis in particular, in patients suffering from AFS. CASE REPORT: A 23 years-old female who presented a primary AFS with a clinical debut consisting of neuropsychiatric manifestations characterized by psychosis (with two delusion episodes) and abnormal movements such as choreiform and hemiballistic movements, initially understood as conversive symptoms. CONCLUSIONS: We discuss the pathogenesis of the psychotic and motor manifestations. The etiology is nowadays not completely understood, but cerebral small vessel thrombosis might explain part of the manifestations. We also review the role of antipsychotic and antithrombotic medication for these patients. Currently, our patient remains asymptomatic without any antipsychotic agent, only being treated with antiagregant and antipalludic therapy.
TITLE: Psicosis como presentacion del sindrome antifosfolipido primario.Introduccion. El sindrome antifosfolipido (SAF) es un trastorno autoinmune que determina un estado de hipercoagulabilidad caracterizado por eventos tromboticos, abortos de repeticion y la presencia de anticuerpos antifosfolipido. Puede presentarse de manera aislada (SAF primario) o asociado a lupus eritematoso sistemico u otras enfermedades autoinmunes (SAF secundario). Las manifestaciones neuropsiquiatricas del SAF incluyen jaqueca, epilepsia, corea, demencia y psicosis. Se realiza una revision bibliografica de la sintomatologia neuropsiquiatrica en general y psicotica en particular de los pacientes afectos de SAF. Caso clinico. Mujer de 23 años afecta de un SAF primario que comenzo con manifestaciones clinicas unicamente neuropsiquiatricas consistentes en sintomatologia psicotica (dos episodios de clinica delirante) y movimientos anormales coreiformes y hemibalisticos que inicialmente se interpretaron como clinica conversiva. Conclusiones. Se discute la patogenesis de la sintomatologia motora y psicotica. La etiologia de los sintomas neuropsiquiatricos todavia no se conoce con claridad, pero la trombosis de pequeños vasos en el cerebro podria explicar parte de los sintomas. Asimismo, se revisa el papel que la medicacion antipsicotica y antitrombotica tiene para estos pacientes. En la actualidad, nuestra paciente se mantiene asintomatica sin necesidad de terapia antipsicotica y recibe tratamiento unicamente con un agente antiagregante y otro antipaludico.